Compare · HYPD vs NVO
HYPD vs NVO
Side-by-side comparison of Hyperion DeFi Inc. (HYPD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 4124.0x HYPD ($44.4M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for HYPD).
- NVO has more recent analyst coverage (25 ratings vs 2 for HYPD).
- Company
- Hyperion DeFi Inc.
- Novo Nordisk A/S
- Price
- $2.88-3.19%
- $41.01-4.51%
- Market cap
- $44.4M
- $183.15B
- 1M return
- -19.44%
- -
- 1Y return
- -33.56%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 4
- 8
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HYPD
- Hyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets
- Hyperion DeFi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Officer Jung Hyunsu bought $29,580 worth of shares (8,000 units at $3.70), increasing direct ownership by 0.58% to 1,385,676 units (SEC Form 4)
- Officer Jung Hyunsu covered exercise/tax liability with 40,000 shares, decreasing direct ownership by 3% to 1,377,676 units (SEC Form 4) to cover taxes
- SEC Form 10-Q filed by Hyperion DeFi Inc.
- Hyperion DeFi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Hyperion DeFi Reports 1Q 2026 Financial Results with Record Net Income and Raises Guidance for Full Year 2026
- Hyperion DeFi Announces Closing of Public Offering of Common Stock
- Hyperion DeFi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Hyperion DeFi Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care